0.00
-0.0011(-23.91%)
Currency In USD
Address
1900 Lake Park Drive
Smyrna, DE 30080
United States of America
Phone
678 384 7220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
September 25, 2020
Name | Title | Pay | Year Born |
Mr. David Alan Dodd | Chairman, President & Chief Executive Officer | 570,300 | 1950 |
Mr. Mark W. Reynolds CPA | Chief Financial Officer & Corporate Secretary | 348,200 | 1962 |
Dr. Mark J. Newman Ph.D. | Chief Scientific Officer | 422,675 | 1955 |
Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer | 501,104 | 1951 |
Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board | 0 | 1938 |
Dr. John W. Sharkey Ph.D. | Vice President of Business Development | 0 | 1956 |
Mr. Thomas O'Brien | Vice President of Quality Systems & Compliance | 0 | N/A |
Mr. Jeffrey Welch | Head of Process Development & Manufacturing Operations | 0 | N/A |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.